The design of clinical trials will change with the use of virtual patients (computer-designed avatars that replicate clinical cases), 3D models and virtual reality.
Single doses. Through cell and gene therapies, Novartis will develop single-dose treatments that will cure or radically change the course of disease.
Mother cells. Research into stem cell therapies (induced pluripotent or CPPi) will create new tools to fight Parkinson’s, Alzheimer’s or certain cancers.
Data. Through devices worn by patients, healthcare professionals will be able to detect physiological alterations or changes in blood glucose levels in real time.
In the oncology area, the use of biomarkers will make it possible to define the prognosis and response to treatment in certain tumors, within a personalized medicine model.